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Keypoints 
• FDG PET-CT is an established tool for response assessment following definitive concurrent
chemoradiotherapy for head and neck squamous cell carcinoma with a high negative
predictive value guiding treatment decisions.
• Little data is available regarding the accuracy of FDG PET-CT for response assessment
following definitive radiotherapy without chemotherapy.
• We retrospectively analysed the accuracy of FDG PET-CT for response assessment following
radiotherapy alone without planned neck dissection in 45 patients.
• PET-CT had a high negative predictive value of 93% and positive predictive value of 88%.
• Based upon the high negative predictive value, PET-CT can be used to avoid surgical
intervention following radiotherapy alone.
Introduction 
Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography  computed tomography (PET-
CT) is established as an accurate tool for response assessment following concurrent chemo-
radiotherapy for head and neck squamous cell carcinoma , with a high negative predictive value 
(NPV), guiding selective surgical intervention 
1-3
.  The phase III PET neck surveillance trial 
demonstrated that PET-CT guided imaging surveillance following concurrent chemo-radiotherapy 
compared with a planned neck dissection achieved similar survival with far fewer neck dissections 
and was cost effective 
2
.  However, the addition of concurrent chemotherapy to radiotherapy is 
often contra-indicated due to comorbidity, and has not been found to be beneficial for patients with 
stage I/II disease, age ш70 years old, WHO performance status ш2 4. There is a paucity of data to 
determine whether response assessment PET-CT after radiotherapy alone is sufficiently accurate to 
influence management. 
In our centre we have adopted a policy of observation if a complete metabolic response on PET-CT is 
achieved following radiotherapy ± chemotherapy 3, 5.  The aim of this report is to analyse the 
accuracy of FDG PET-CT response assessment following radiotherapy alone without a planned neck 
dissection. 
Methods 
Ethical considerations 
The study was registered with the Institutional Quality Improvement Board. 
Study design 
45 consecutive patients with head and neck squamous cell carcinoma who underwent FDG PET-CT 
for response assessment following curative-intent radiotherapy (without chemotherapy) between 
2009-2014 were retrospectively identified.  Inclusion criteria were i) squamous cell carcinoma of the 
oropharynx, larynx, hypopharynx or unknown primary ii) radiotherapy with curative intent, iii) FDG 
PET-CT as a baseline prior to treatment.  Patients with prior therapeutic resection of primary and/or 
lymph node disease were excluded. 
Response assessment 
Tumour response was routinely assessed 4 months after the completion of radiotherapy by clinical 
examination and FDG PET-CT (according to previously described imaging protocols 
3, 5
). Planned neck 
dissections were not performed.   
Categorisation of FDG PET-CT response assessment 
Categorisation of FDG PET-CT response was based upon radiology reports as previously described 
3, 5
. 
Results of post-treatment FDG PET-CT were qualitatively categorised into complete, equivocal or 
incomplete for the primary site and nodal sites separately. A complete response was defined as the 
absence of any abnormal focal FDG uptake or diffuse FDG uptake in the absence of corresponding 
anatomical abnormality on the CT which was considered to be radiotherapy related.  An incomplete 
response was defined as focal uptake, corresponding to a structural abnormality and of greater 
intensity than background liver activity.  Scans were classed as equivocal if focal FDG uptake was 
below liver background but above that of surrounding normal tissues. 
Analysis and statistics 
Duration of follow up was defined from final day of radiotherapy.  Sensitivity, specificity, positive 
predictive value (PPV) and NPV were calculated using 2x2 tables constructed using clinico-
pathological outcomes. 
Results 
Median follow up for living patients was 32 months (range 8-65).  Median age was 68 years (range 
40-83).  32/45 (71%) were male.  Disease and treatment characteristics are shown in Table 1.  
Reasons for not delivering chemotherapy concurrently with radiotherapy were: age ш70 years old in 
19 patients, early stage disease (stage I/II) in 10 patients (including 1 patient ш70 years old), 
comorbidity/limited performance status in 15, social situation in 1, patient choice in 1.  
On pre-treatment PET-CT 37 patients had an FDG-avid primary lesion and the median primary 
tumour maximum SUV was 11.9 (range 2.9-53). 31 patients had FDG-avid lymph node disease on 
baseline PET-CT and the median lymph node maximum SUV was 9 (range 3-14.5). Median time to 
response assessment FDG PET-CT following radiotherapy was 17.6 weeks (range 13-22 weeks).  
Overall, 29 of 45 (64%) patients had a locoregional complete metabolic response.  Overall, treatment 
failure at the primary site and lymph nodes occurred in 10/45 (22%) and 11/45 (24%) patients 
respectively (including combined primary and nodal treatment failure in 4 patients).  Table 2 
demonstrates the sensitivity, specificity, PPV and NPV for the response assessment FDG PET-CT 
outcomes. Where primary tumour or lymph nodes were not assessable on the baseline FDG PET-CT 
these were omitted from the analysis of the respective response assessments. 
With regard to the primary site, a complete metabolic response was demonstrated in 27 of 36 (75%) 
of patients with an FDG-avid primary site at baseline assessment; NPV was 92%. FDG uptake 
suggestive of persistent disease was present in 8 of 36 patients (22%), and an equivocal response in 
2 of 36 (6%) patients.  Median SUV in the incomplete and equivocal FDG PET-CT group for primary 
site was 5.6 (range 3.9-10.9).  For the primary tumour site demonstrating an incomplete (n=8) or 
equivocal response (n=2), status was determined for analysis on the basis of biopsy, surgery and 
subsequent clinical progression/ follow up in 5, 2 and 3 patients respectively.  PPV combining 
incomplete and equivocal scans was 80%, PPV for incomplete response scans alone was 75%.  Both 
patients with equivocal uptake in the primary site has subsequently proven residual disease. 
With regard to lymph node disease, a complete metabolic response was demonstrated in 20 of 31 
(65%) of patients with FDG-avid nodal disease at baseline; NPV was 95%. FDG uptake suggestive of 
persistent disease was present in 9 of 31 (29%), and equivocal response in 2 of 31 (6%).  Median SUV 
in the incomplete and equivocal FDG PET-CT group for lymph nodes was 4.7 (range 2.8-9.6).  For 
lymph nodes demonstrating an incomplete (n=9) or equivocal response (n=2), status was 
determined for the analysis on the basis of subsequent clinical progression/ follow up, biopsy and 
neck dissection in 7, 3 and 1 patients respectively.  PPV combining incomplete and equivocal scans 
was 91%; PPV for incomplete response scans alone was 78%.  Both patients with equivocal lymph 
node uptake had evidence of persistent disease (neck dissection in one, and clinical regional 
progression with distant disease in the other). 
8 of 45 (18%) of patients had new distant metastatic disease detected on response assessment FDG 
PET-CT (4 with complete locoregional response): 5 developed lung metastases, 2 lung and bone 
metastases, and one liver metastases.  
Discussion 
The accuracy of a test depends upon the population to which it is applied and the accuracy of PET-CT 
for response assessment may vary depending upon treatment strategy. To guide a surveillance 
strategy following radiotherapy alone, which is a less intensive treatment than chemo-radiotherapy, 
it is essential to determine whether the NPV of FDG PET-CT is high with regard to both primary and 
nodal disease. 
Synopsis of key findings 
In this series of 45 patients, the NPV of a complete metabolic response of PET-CT was high, 92%, 95% 
and 93% for the primary site, lymph nodes and overall.  The PET-CT response scan was false negative 
in 2/45 (4%) patients.  The PPV of incomplete response or equivocal FDG uptake grouped together 
was high, 80%, 91% and 88% for primary site, lymph nodes and overall.  Overall sensitivity and 
specificity were high (88% and 93% respectively).  Despite the use of PET-CT for staging pre-
treatment, 18% of patients were found to have developed distant metastatic disease on response 
assessment PET-CT. 
Study limitations 
Limitations include the retrospective nature of the analysis, along with the limited size of study 
population.  Few patients had an equivocal response, precluding conclusions regarding optimal 
management of this subgroup.  Human papilloma virus testing was not routinely available for 
patients treated in this era. 
Comparison with other studies 
To the best of our knowledge there are no other reports of FDG PET-CT for response assessment 
exclusively following radiotherapy alone. Multiple studies have examined PET-CT following patients 
treated exclusively with chemo-radiotherapy 6, 7 or including a majority of patients receiving 
chemotherapy 3, 8.  Within these single centre studies the NPVs for the primary lesion and lymph 
nodes are consistently high (98-100% and 91-99% respectively).  By contrast, PPVs are more limited 
(33-81% and 61-83% respectively).  In a meta-analysis 1 including predominantly studies of PET-CT 
post-chemoradiotherapy, the PPV and NPV for primary site and lymph nodes of PET was found to be 
58.6%, 95.1% and 52.1% and 94.5% respectively.  By comparison with these studies, the NPV for 
primary and lymph nodes in the current series after radiotherapy alone is in a similar range, whilst 
the PPVs of primary and lymph nodes is higher than might have been anticipated.  Consistent with 
our data on NPV is a prior study of early PET-CT 6 weeks post-treatment 
9
 which reported on a series 
of patients with human papilloma virus-positive oropharyngeal carcinoma of whom 92% received 
radiotherapy alone; NPV was 94% and a PPV of 56%.  The cause of the high PPV in our series is 
unclear and may be related to small sample size.  PET-CT performed at differing timepoints may 
have differing accuracy and the delayed timing of PET-CT may have led to an improved PPV.  Meta-
analysis has shown that PET-CT performed ш12 weeks post treatment improves diagnostic accuracy 
1. Along with others 10, we have previously adopted a policy of performing response assessment 4
months post-treatment.
Summary 
FDG PET-CT response assessment following radiotherapy alone has a high NPV for both primary site 
and lymph nodes and can be used to guide treatment decisions to avoid the need for further 
investigation and neck dissection respectively. 
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Table 1: Disease site, TNM stage, AJCC stage, histology and treatment 
Characteristic Number (%)
Primary tumour site: 
  Oropharynx 
  Oral cavity 
  Hypopharynx 
  Larynx 
 Unknown primary  
27 (60%) 
1 (2%) 
5 (11%) 
6 (13%) 
6 (13%) 
T stage 
  T0 
  T1 
  T2 
  T3 
  T4 
5 (11%) 
5 (11%) 
15 (33%) 
11 (24%) 
9 (20%) 
Nodal (N) stage 
  N0 
  N1 
  N2a 
  N2b 
  N2c 
  N3 
14 (31%) 
5 (11%) 
2 (4%) 
18 (40%) 
6 (13%) 
0 (0%) 
Metastases (M) stage 
  M0 45 (100%) 
Stage 
    II 
    III 
    IV 
10 (22%) 
8 (18%) 
27 (60%) 
Histology 
SCC 45 (100%) 
Radiotherapy dose schedule 
  70Gy in 35 fractions 
  65Gy in 30 fractions 
43 (96%) 
2 (4%) 
Table 2: Diagnostic performance of response assessment FDG PET-CT in patients with head and neck 
cancer after radiotherapy (incomplete or equivocal responses grouped together for analysis) 
Primary site (n=36) Neck nodes (n=26) Overall (primary and 
neck (excluding distant 
metastases) (n=45) 
FDG PET-CT incomplete 
or equivocal response 
10 11 16
FDG PET-CT complete 
response 
26 20 29
True positive 8 10 14 
True negative 24 19 27 
False positive 2 1 2
False negative 2 1 2
Sensitivity 80% 91% 88%
Specificity 92% 95% 93%
Positive predictive value 80% 91% 88% 
Negative predictive value 92% 95% 93% 
